Immunotherapy targeting <scp>isoDGR</scp> ‐protein damage extends lifespan in a mouse model of protein deamidation

Pazhanichamy Kalailingam, Khalilatul‐Hanisah Mohd‐Kahliab, SoFong Cam Ngan, Ranjith Iyappan, Evelin Melekh, Tian Lu, Gan Wei Zien, Bhargy Sharma, Tiannan Guo, Adam J. MacNeil, Rebecca E. K. MacPherson, Evangelia Tsiani, Deborah D. O’Leary, Kah‐Leong Lim, I-hsin Su, Yong‐Gui Gao, Mark Richards, Raj N. Kalaria, Christopher Chen, Neil E. McCarthy, Siu Kwan SzeEMBO 2023 · DOI

TL;DR

This study reveals that a specific type of protein damage, isoDGR, accumulates with age and drives chronic inflammation, contributing to reduced lifespan. By developing an immunotherapy that targets and clears these damaged proteins, the researchers significantly extended lifespan and improved health in a mouse model of aging. This work suggests that targeting age-related protein damage could be a novel therapeutic strategy for various degenerative diseases.

What Problem Does This Paper Address?

Aging is characterized by a gradual decline in bodily functions and an increased susceptibility to chronic diseases. At a molecular level, this decline is often attributed to the accumulation of damage to biomolecules, including proteins. One such type of damage is deamidation, where amino acids like asparagine can undergo a conformational change to isoaspartate. The researchers previously identified that a specific deamidation event in the NGR (Asn-Gly-Arg) sequence, leading to isoDGR (isoAsp-Gly-Arg), creates a "gain-of-function" motif. This isoDGR motif can bind to integrins on immune cells, activating them and promoting chronic inflammation, a hallmark of age-related diseases like cardiovascular disorders. However, the precise role of this isoDGR damage in aging and whether it could be therapeutically targeted remained unclear. This paper aims to investigate the impact of isoDGR accumulation on lifespan and healthspan and to test the efficacy of an immunotherapy designed to clear these damaged proteins.

Methods

The study employed a multi-pronged approach:

  • Mouse Models: They utilized Pcmt1<sup>-/-</sup> mice, which lack a crucial protein repair enzyme and thus exhibit accelerated accumulation of isoaspartate damage, mimicking aspects of natural aging. They also used naturally aged wild-type (WT) mice.
  • Immunotherapy: A monoclonal antibody (mAb) specifically targeting the isoDGR motif was developed and administered weekly to the mice.
  • Biochemical Analysis: Western blotting and immunostaining were used to quantify isoDGR-modified protein levels in various tissues (brain, liver, spleen, thymus) and to assess the infiltration of immune cells (CD68+ macrophages).
  • Functional Assays: Motor function was evaluated using hind-limb clasping and ledge tests.
  • Inflammation Assessment: Real-time PCR and multiplex bead arrays were used to measure the levels of pro-inflammatory cytokines in both tissue lysates and blood plasma.
  • In Vitro Assays: Antibody-dependent cellular phagocytosis (ADCP) assays were performed using RAW macrophages to investigate the mechanism of immune clearance.
  • Induction of Damage: To confirm the causal role of isoDGR, plasma proteins and synthetic peptides were modified in vitro to create isoDGR motifs and then injected into young WT mice.

Datasets

Not explicitly discussed as distinct datasets in the paper. The primary "datasets" are the experimental results obtained from the mouse models and in vitro assays described in the Methods section.

Key Insights and Ideas

  • IsoDGR as a "Molecular Clock" Driver: The accumulation of isoDGR is not just a passive marker of aging but actively drives pathology by promoting chronic inflammation. This suggests it could be a more direct driver of age-related decline than previously appreciated.
  • Targeting Protein Damage for Longevity: The success of the anti-isoDGR immunotherapy demonstrates that directly clearing damaged proteins, rather than solely relying on endogenous repair mechanisms, can have a profound impact on lifespan and healthspan.
  • ADCP as the Key Clearance Mechanism: The study clearly shows that the anti-isoDGR mAb works by flagging damaged proteins for clearance by macrophages through ADCP, highlighting a crucial role for this immune mechanism in combating age-related molecular damage.
  • IsoDGR Induces Inflammation Systemically: The findings that isoDGR-modified proteins can induce inflammation even when experimentally introduced into young, healthy animals underscore the potent and widespread inflammatory potential of this damage.

Key Results

  • Lifespan Extension: Weekly administration of anti-isoDGR mAb doubled the average lifespan of Pcmt1<sup>-/-</sup> mice.
  • Improved Healthspan: Treated Pcmt1<sup>-/-</sup> mice showed improved body weight, better motor function (reduced hind-limb clasping, improved ledge test scores), and enhanced coordination.
  • Reduced Inflammation: The immunotherapy significantly decreased levels of pro-inflammatory cytokines in both plasma and tissues of Pcmt1<sup>-/-</sup> mice and naturally aged WT mice.
  • Decreased IsoDGR Levels: Western blot analysis confirmed a significant reduction in isoDGR-modified protein levels in the brain and liver of treated mice.
  • Macrophage Activation and Clearance: In vitro and in vivo experiments demonstrated that the anti-isoDGR mAb effectively promoted the phagocytosis of isoDGR-modified proteins by macrophages via ADCP.
  • Age-Dependent Accumulation: IsoDGR levels and CD68+ macrophage infiltration in the liver increased with age in WT and Pcmt1<sup>+/-</sup> mice, with a more pronounced effect in the latter.

Limitations and Future Work

  • Mouse Model Specificity: While Pcmt1<sup>-/-</sup> mice provide a valuable model for accelerated damage, the findings need to be validated in more diverse aging models and, ultimately, in humans.
  • Broader DPMs: The study focuses specifically on isoDGR. Future work could explore whether similar immunotherapeutic strategies could be developed for other types of age-related protein damage (e.g., oxidation, glycation).
  • Long-Term Effects: While lifespan was extended, further research could investigate the long-term impact of this immunotherapy on a wider range of age-related pathologies and cognitive functions.
  • Translational Potential: The authors suggest that this approach could be an effective intervention for human degenerative disorders, but significant translational research would be required to move this therapy from mice to humans.

Summary updated

Abstract

Aging results from the accumulation of molecular damage that impairs normal biochemical processes. We previously reported that age-linked damage to amino acid sequence NGR (Asn-Gly-Arg) results in "gain-of-function" conformational switching to isoDGR (isoAsp-Gly-Arg). This integrin-binding motif activates leukocytes and promotes chronic inflammation, which are characteristic features of age-linked cardiovascular disorders. We now report that anti-isoDGR immunotherapy mitigates lifespan reduction of Pcmt1<sup>-/-</sup> mouse. We observed extensive accumulation of isoDGR and inflammatory cytokine expression in multiple tissues from Pcmt1<sup>-/-</sup> and naturally aged WT animals, which could also be induced via injection of isoDGR-modified plasma proteins or synthetic peptides into young WT animals. However, weekly injection of anti-isoDGR mAb (1 mg/kg) was sufficient to significantly reduce isoDGR-protein levels in body tissues, decreased pro-inflammatory cytokine concentrations in blood plasma, improved cognition/coordination metrics, and extended the average lifespan of Pcmt1<sup>-/-</sup> mice. Mechanistically, isoDGR-mAb mediated immune clearance of damaged isoDGR-proteins via antibody-dependent cellular phagocytosis (ADCP). These results indicate that immunotherapy targeting age-linked protein damage may represent an effective intervention strategy in a range of human degenerative disorders.
BibTeX
@inproceedings{kalailingam2023immunotherapy,
  author = {Pazhanichamy Kalailingam and Khalilatul‐Hanisah Mohd‐Kahliab and SoFong Cam Ngan and Ranjith Iyappan and Evelin Melekh and Tian Lu and Gan Wei Zien and Bhargy Sharma and Tiannan Guo and Adam J. MacNeil and Rebecca E. K. MacPherson and Evangelia Tsiani and Deborah D. O’Leary and Kah‐Leong Lim and I-hsin Su and Yong‐Gui Gao and Mark Richards and Raj N. Kalaria and Christopher Chen and Neil E. McCarthy and Siu Kwan Sze},
  title = {{Immunotherapy targeting <scp>isoDGR</scp> ‐protein damage extends lifespan in a mouse model of protein deamidation}},
  booktitle = {EMBO},
  year = {2023},
  doi = {10.15252/emmm.202318526},
}
Figure